Multiple Myeloma Trials
Select Clinical Trial
Protocol Number: DRAMMATIC Study (SWOG 1803)
Protocol Title: PHASE III STUDY OF DARATUMUMAB/rHuPH20 (NSC- 810307) + LENALIDOMIDE OR LENALIDOMIDE AS POST-AUTOLOGOUS STEM CELL TRANSPLANT MAINTENANCE THERAPY IN PATIENTS WITH MULTIPLE MYELOMA (MM) USING MINIMAL RESIDUAL DISEASE TO DIRECT THERAPY DURATION
Eligibility: Men or women, ages 18 and older with Multiple Myeloma, after an autologous stem cell transplant
Contact Information: (910) 715-2200